Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
A Japanese health ministry panel on December 18 approved a plan to add shingles vaccines to the list of jabs to be covered by the national immunization program (NIP) from FY2025, basically targeting people aged 65. Starting on April 1,…
To read the full story
Related Article
- Shingles Shots Added to NIP, HPV Catch-Up Program Extended: MHLW
April 7, 2025
- GSK’s Shingrix Buttresses Label with Long-Term Data
April 2, 2025
- GSK Vows to Ensure Proper Use of Shingles Jab towards NIP Inclusion
March 3, 2025
- MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan
January 30, 2025
- GSK Applauds Japan’s Plan to Include Shingles Vaccines in NIP
December 19, 2024
- Japan Expected to Include Shingles Vaccines in NIP from FY2025
December 4, 2024
- Pfizer Rolls Out Prevenar 20 in Japan, Pediatric NIP Set to Start October
September 2, 2024
- Prevenar 20 to Join National Immunization for Children from October
August 1, 2024
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- Japan Panel Raises No Objection to Public Coverage of Shingles Vaccines
June 21, 2024
- MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
May 24, 2024
REGULATORY
- Keytruda SC Tops New NHI Listing Round with 75 Billion Yen Sales Outlook
November 9, 2026
- Japan Set to Prioritize Pharma in Growth Strategy Action Plan
November 9, 2026
- Japan to Delist 657 Drugs, Including ActHIB and Alofisel
November 9, 2026
- Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
November 6, 2026
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…